Jindalai (688057.SH) plans to increase capital by 280 million yuan to invest in Keats Healthcare

Zhitong Finance App News, Jindalai (688057.SH) issued an announcement. Based on optimism about the development prospects of strategic emerging industries in the country, such as the development and application of stem cell technology, the company plans to gradually optimize the company's industrial structure and find new industrial opportunities for future development, so as to enhance the company's resilience to risks and cultivate new profit growth points. The company plans to use its own capital of 280 million yuan to increase capital to Yunnan Jici Medical Technology Co., Ltd. (“Jici Medical”). After the transaction is completed, the company will hold 34% of Keats Healthcare's shares.

The target company has unique advantages in the field of reverse cell differentiation and rejuvenation and its regulation. It has independently established a technical system that uses non-genetic modification technology to induce skin fibroblasts into specific functional cells, and has developed inducible mesenchymal stem cells (iMSC) without going through the inducible pluripotent stem cell (iPSC) stage and functional activity not limited by age. The target company refers to first-generation iMSC as “rFIb”, and inducible osteoblasts (iCB), inducible chondrocytes (iSCs), inducible chondrocytes (ICh). Neurons (Inc), Induced endothelial cells (IEC) and induced vascular smooth muscle cells (IVSMC) series of autologous cell preparations or derivatives thereof (such as exosomes, cytokines, mitochondria, collagen, tissue engineering materials, etc.).

In particular, the target company has developed a new field of autologous cell therapy and tissue engineering research for intractable diseases, especially intractable geriatric diseases, and has obtained 20 invention patents in China, the United States, Japan, Canada, Australia, Malaysia and other countries.